Volume | 127,215 |
|
|||||
News | - | ||||||
Day High | 3.94 | Low High |
|||||
Day Low | 3.76 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.83 | 3.76 | 3.94 | 3.85 | 3.82 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,756 | 127,215 | US$ 3.83 | US$ 486,664 | - | 3.2101 - 23.52 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:58:53 | 25 | US$ 3.83 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
49.74M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
Date | Time | Source | News Article |
---|---|---|---|
5/29/2024 | 07:20 | Edgar (US Regulatory) | Form 8-K - Current report |
5/22/2024 | 08:08 | Edgar (US Regulatory) | Form 8-K - Current report |
5/15/2024 | 08:29 | Edgar (US Regulatory) | Form 8-K - Current report |
5/10/2024 | 16:27 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
3/08/2024 | 15:49 | Edgar (US Regulatory) | Form 8-K - Current report |
3/01/2024 | 15:40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
3/01/2024 | 06:35 | Edgar (US Regulatory) | Form 8-K - Current report |
2/29/2024 | 19:23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/29/2024 | 15:44 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/29/2024 | 07:09 | Edgar (US Regulatory) | Form 8-K - Current report |
2/14/2024 | 16:09 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial.. |
2/13/2024 | 14:53 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.73 | 3.94 | 3.50 | 3.65 | 130,672 | 0.12 | 3.22% |
1 Month | 4.71 | 4.98 | 3.2101 | 3.74 | 165,904 | -0.86 | -18.26% |
3 Months | 5.21 | 5.40 | 3.2101 | 4.35 | 148,018 | -1.36 | -26.10% |
6 Months | 5.44 | 6.81 | 3.2101 | 4.93 | 203,217 | -1.59 | -29.23% |
1 Year | 20.03 | 23.52 | 3.2101 | 9.50 | 189,346 | -16.18 | -80.78% |
3 Years | 40.69 | 58.25 | 3.2101 | 26.68 | 154,933 | -36.84 | -90.54% |
5 Years | 51.53 | 64.94 | 3.2101 | 35.29 | 150,947 | -47.68 | -92.53% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |